ProPhase Labs' Executive Equity Awards Hit Zero in 2023-2024

TL;DR

**ProPhase Labs' execs got no new stock awards in 2023-2024, signaling a potential lack of long-term equity alignment; this is bearish for future growth incentives.**

AI Summary

ProPhase Labs, Inc. (PRPH) filed its DEF 14A on June 23, 2025, outlining executive compensation for the fiscal years ending December 31, 2023, and December 31, 2024. The filing details the aggregate value of stock and option awards for Persons Employed by the Organization (PEOs) and Non-PEO Named Executive Officers (NEOs). For PEOs, the aggregate value of stock and option awards included in the Summary Compensation Table (SCT) was $0 for both 2023 and 2024, indicating no new awards were granted or included in the SCT during these periods. Similarly, Non-PEO NEOs also showed $0 in aggregate stock and option awards for both years. The fair value at year-end of awards granted during the covered fiscal year that were outstanding and unvested was also $0 for both PEOs and Non-PEO NEOs in 2023 and 2024, suggesting a lack of new equity grants or a full vesting schedule within the year. The year-over-year change in fair value of prior awards outstanding and unvested was also $0 for all categories, reinforcing the absence of significant unvested equity compensation. The vesting date fair value of awards granted and vested during the covered fiscal year was also $0 for both PEOs and Non-PEO NEOs in 2023 and 2024, indicating no equity awards vested during these periods. This suggests a compensation strategy heavily reliant on cash or a prior equity grant cycle that has largely concluded.

Why It Matters

This DEF 14A filing reveals a striking absence of new equity compensation for ProPhase Labs' executives in 2023 and 2024, with aggregate stock and option awards reported at $0. For investors, this could signal a shift in compensation strategy, potentially favoring cash bonuses or indicating a period of limited new equity incentives, which might impact executive retention and long-term alignment with shareholder interests. Employees, particularly those in leadership, might view this as a lack of future upside tied to stock performance, potentially affecting morale and competitive positioning against pharmaceutical peers like Pfizer or Johnson & Johnson, which often use robust equity programs. Customers and the broader market may not be directly impacted, but a less incentivized executive team could indirectly affect strategic innovation and growth, crucial for a pharmaceutical preparations company.

Risk Assessment

Risk Level: medium — The risk level is medium because the absence of new equity awards for executives in 2023 and 2024, as indicated by $0 values for aggregate stock and option awards, could lead to reduced long-term incentive alignment. This lack of equity-based compensation might disincentivize executives from focusing on sustained shareholder value creation, potentially impacting future performance and retention.

Analyst Insight

Investors should scrutinize ProPhase Labs' upcoming earnings calls for explanations regarding this compensation strategy and its potential impact on executive retention and long-term strategic initiatives. Consider if this shift to non-equity compensation aligns with the company's growth objectives and competitive landscape.

Key Numbers

• $0 — Aggregate value for stock awards and option awards for PEOs (Reported for both 2023 and 2024, indicating no new equity awards.)
• $0 — Aggregate value for stock awards and option awards for Non-PEO NEOs (Reported for both 2023 and 2024, indicating no new equity awards.)
• $0 — Fair value at year-end of unvested awards for PEOs (Reported for both 2023 and 2024, suggesting no outstanding unvested equity.)
• $0 — Fair value at year-end of unvested awards for Non-PEO NEOs (Reported for both 2023 and 2024, suggesting no outstanding unvested equity.)
• $0 — Vesting date fair value of awards granted and vested for PEOs (Reported for both 2023 and 2024, indicating no equity awards vested.)
• $0 — Vesting date fair value of awards granted and vested for Non-PEO NEOs (Reported for both 2023 and 2024, indicating no equity awards vested.)
• 2025-06-23 — Filing Date (Date the DEF 14A was filed with the SEC.)
• 1993-03-28 — Date of Name Change (When QUIGLEY CORP became ProPhase Labs, Inc.)
• 12-31 — Fiscal Year End (ProPhase Labs' fiscal year ends on December 31st.)
• 000-21617 — SEC File Number (Unique identifier for ProPhase Labs' SEC filings.)

Key Players & Entities

• ProPhase Labs, Inc. (company) — Filer of DEF 14A
• SEC (regulator) — Recipient of DEF 14A filing
• 03 Life Sciences (company) — Organization Name associated with ProPhase Labs
• QUIGLEY CORP (company) — Former name of ProPhase Labs
• Persons Employed by the Organization (person) — Category of executive compensation recipients
• Non-PEO Named Executive Officers (person) — Category of executive compensation recipients
• Garden City (location) — City of ProPhase Labs' business address
• New York (location) — State of ProPhase Labs' business address
• Delaware (location) — State of incorporation for ProPhase Labs
• Bloomberg (company) — Publisher of this analysis

FAQ

Industry Context

ProPhase Labs operates within the pharmaceutical preparations sector, a highly competitive and regulated industry. Companies in this space focus on research, development, manufacturing, and marketing of drugs and other healthcare products. Key trends include the increasing demand for innovative treatments, the impact of regulatory approvals, and the pressure to manage costs effectively. The industry is characterized by significant R&D investment and a complex supply chain.

Regulatory Implications

As a pharmaceutical company, ProPhase Labs is subject to stringent regulations from bodies like the FDA. Compliance with manufacturing standards (cGMP), drug approval processes, and marketing regulations is critical. Any failure to adhere to these regulations can result in significant fines, product recalls, and reputational damage, impacting financial performance and investor confidence.

What Investors Should Do

1. Investigate the rationale behind the absence of equity compensation.
2. Review the company's overall financial health and operational performance.
3. Monitor future filings for any changes in executive compensation structure.

Key Dates

• 2025-06-23: DEF 14A Filing — Provides detailed information on executive compensation and corporate governance for the fiscal years ending December 31, 2023, and December 31, 2024.
• 1993-03-28: Name Change to ProPhase Labs, Inc. — Marks the transition from its former identity as QUIGLEY CORP, indicating a potential shift in business focus or strategy.
• 2024-12-31: Fiscal Year End — The end date for the reporting periods covered in the DEF 14A, crucial for understanding the financial and compensation data presented.
• 2023-12-31: Fiscal Year End — The prior fiscal year end, used for comparative analysis of compensation and performance metrics.

Glossary

DEF 14A

A filing required by the U.S. Securities and Exchange Commission (SEC) that provides detailed information about executive compensation, corporate governance, and other matters related to a company's annual meeting of shareholders. (This filing is the primary source of information for executive compensation analysis, revealing how the company compensates its top executives.)

Summary Compensation Table (SCT)

A table within the DEF 14A that summarizes the compensation of the company's Named Executive Officers (NEOs) for the last three fiscal years. (Provides a standardized view of total compensation, including salary, bonuses, stock awards, and other incentives, for key executives.)

Persons Employed by the Organization (PEOs)

Refers to individuals who are officers or directors of the company, or who hold significant executive positions. (This category includes the highest-ranking executives whose compensation is detailed in the filing.)

Non-PEO Named Executive Officers (Non-PEO NEOs)

Refers to executive officers who are not considered PEOs but are still designated as Named Executive Officers, often due to their role or compensation level. (This category captures other key executives whose compensation is reported, providing a broader view of executive pay.)

Stock Awards and Option Awards

Forms of equity-based compensation granted to executives, where stock awards represent direct ownership of company stock and option awards give the right to purchase stock at a predetermined price. (These are significant components of executive pay, often used to align executive interests with shareholder value. The absence of these in the SCT is a key finding.)

Year-Over-Year Comparison

This DEF 14A filing for the fiscal years ending December 31, 2023, and December 31, 2024, presents a stark contrast to typical executive compensation disclosures. The complete absence of reported stock and option awards for both PEOs and Non-PEO NEOs across all relevant metrics (aggregate value, unvested awards, vested awards) indicates a significant departure from equity-based incentive structures. This suggests either a deliberate strategy to rely solely on cash compensation or that prior equity grants have fully vested or expired, with no new grants issued during these periods. Further analysis would require comparing this to previous filings to understand the historical trend of equity awards.

Filing Details

This Form DEF 14A (Form DEF 14A) was filed with the SEC on June 23, 2025 by Persons Employed by the Organization regarding ProPhase Labs, Inc. (PRPH).

View full filing on EDGAR

View Full Filing

View this DEF 14A filing on SEC EDGAR